Literature DB >> 35007329

Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.

Edward J Boyko1,2, Leila R Zelnick2, Barbara H Braffett3, Rodica Pop-Busui4, Catherine C Cowie5, Gayle M Lorenzi6, Rose Gubitosi-Klug7, Bernard Zinman8, Ian H de Boer1,2.   

Abstract

OBJECTIVE: Intensive glycemic control reduces the risk of kidney, retinal, and neurologic complications in type 1 diabetes (T1D), but whether it reduces the risk of lower-extremity complications is unknown. We examined whether former intensive versus conventional glycemic control among Diabetes Control and Complications Trial (DCCT) participants with T1D reduced the long-term risk of diabetic foot ulcers (DFUs) and lower-extremity amputations (LEAs) in the subsequent Epidemiology of Diabetes Interventions and Complications (EDIC) study. RESEARCH DESIGN AND METHODS: DCCT participants (n = 1,441) completed 6.5 years on average of intensive versus conventional diabetes treatment, after which 1,408 were enrolled in EDIC and followed annually over 23 years for DFU and LEA occurrences by physical examination. Multivariable Cox proportional hazard regression models estimated associations of DCCT treatment assignment and time-updated exposures with DFU or LEA.
RESULTS: Intensive versus conventional glycemic control was associated with a significant risk reduction for all DFUs (hazard ratio 0.77 [95% CI 0.60, 0.97]) and a similar magnitude but nonsignificant risk reduction for first-recorded DFUs (0.78 [0.59, 1.03]) and first LEAs (0.70 [0.36, 1.36]). In adjusted Cox models, clinical neuropathy, lower sural nerve conduction velocity, and cardiovascular autonomic neuropathy were associated with higher DFU risk; estimated glomerular filtration rate <60 mL/min/1.73 m2, albuminuria, and macular edema with higher LEA risk; and any retinopathy and greater time-weighted mean DCCT/EDIC HbA1c with higher risk of both outcomes (P < 0.05).
CONCLUSIONS: Early intensive glycemic control decreases long-term DFU risk, the most important antecedent in the causal pathway to LEA.
© 2022 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35007329      PMCID: PMC8914413          DOI: 10.2337/dc21-1816

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  29 in total

1.  Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.

Authors:  Naji Younes; Patricia A Cleary; Michael W Steffes; Ian H de Boer; Mark E Molitch; Brandy N Rutledge; John M Lachin; William Dahms
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

2.  A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study.

Authors:  E J Boyko; J H Ahroni; V Stensel; R C Forsberg; D R Davignon; D G Smith
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

3.  A prospective study of risk factors for foot ulceration: the West of Ireland Diabetes Foot Study.

Authors:  L Hurley; L Kelly; A P Garrow; L G Glynn; C McIntosh; A Alvarez-Iglesias; G Avalos; S F Dinneen
Journal:  QJM       Date:  2013-09-25

4.  Pathways to diabetic limb amputation. Basis for prevention.

Authors:  R E Pecoraro; G E Reiber; E M Burgess
Journal:  Diabetes Care       Date:  1990-05       Impact factor: 19.112

5.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  Muscle weakness and foot deformities in diabetes: relationship to neuropathy and foot ulceration in caucasian diabetic men.

Authors:  Carine H M van Schie; Cristiana Vermigli; Anne L Carrington; Andrew Boulton
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

7.  Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial.

Authors:  Rickey E Carter; Daniel T Lackland; Patricia A Cleary; Eunsil Yim; Maria F Lopes-Virella; Gregory E Gilbert; Trevor J Orchard
Journal:  Diabetes Care       Date:  2007-07-10       Impact factor: 19.112

8.  Effect of Intensive Glycemic Control on Risk of Lower Extremity Amputation.

Authors:  Matthew P Goldman; Christopher J Clark; Timothy E Craven; Ross P Davis; Timothy K Williams; Gabriela Velazquez-Ramirez; Justin B Hurie; Matthew S Edwards
Journal:  J Am Coll Surg       Date:  2018-10-16       Impact factor: 6.113

9.  Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  Rachel G Miller; Aaron M Secrest; Demetrius Ellis; Dorothy J Becker; Trevor J Orchard
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

10.  The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview.

Authors:  David M Nathan
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

View more
  3 in total

Review 1.  Learning by reading: A review of recent diabetes articles.

Authors:  Zachary Bloomgarden
Journal:  J Diabetes       Date:  2022-05-23       Impact factor: 4.530

2.  Temporal trends in patients with peripheral artery disease influenced by diabetes mellitus in Germany.

Authors:  Volker H Schmitt; Lukas Hobohm; Markus Vosseler; Christoph Brochhausen; Thomas Münzel; Christine Espinola-Klein; Karsten Keller
Journal:  J Diabetes       Date:  2022-09-22       Impact factor: 4.530

Review 3.  Recent advances of the nanocomposite hydrogel as a local drug delivery for diabetic ulcers.

Authors:  Sen Tong; Qingyu Li; Qiaoyan Liu; Bo Song; Junzi Wu
Journal:  Front Bioeng Biotechnol       Date:  2022-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.